These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9455797)

  • 1. Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D.
    Prados J; Melguizo C; Marchal JA; Vélez C; Alvarez L; Aránega A
    Int J Cancer; 1998 Jan; 75(3):379-83. PubMed ID: 9455797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug resistance phenotype in the RMS-GR human rhabdomyosarcoma cell line obtained after polychemotherapy.
    Prados J; Melguizo C; Marchal JA; Vélez C; Alvarez L; Aránega A
    Jpn J Cancer Res; 1999 Jul; 90(7):788-93. PubMed ID: 10470293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low concentrations of actinomycin D potentially cause therapeutic differentiation in human rhabdomyosarcoma cell line RD.
    Melguizo C; Prados J; Marchal JA; Aránega AE; Alvarez L; Aránega A
    Pathol Res Pract; 1996 Feb; 192(2):188-94. PubMed ID: 8692721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actinomycin D treatment leads to differentiation and inhibits proliferation in rhabdomyosarcoma cells.
    Marchal JA; Prados J; Melguizo C; Fernández JE; Vélez C; Alvarez L; Aránega A
    J Lab Clin Med; 1997 Jul; 130(1):42-50. PubMed ID: 9242365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actinomycin D causes multidrug resistance and differentiation in a human rhabdomyosarcoma cell line.
    Melguizo C; Prados J; Fernández JE; Vélez C; Alvarez L; Aránega A
    Cell Mol Biol (Noisy-le-grand); 1994 Mar; 40(2):137-45. PubMed ID: 7911694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
    Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse expression of mdr 1 and c-myc genes in a rhabdomyosarcoma cell line resistant to actinomycin d.
    Prados J; Melguizo C; Fernández A; Aránega AE; Alvarez L; Aránega A
    J Pathol; 1996 Sep; 180(1):85-9. PubMed ID: 8943821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
    Stein U; Walther W; Shoemaker RH
    J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells.
    Melguizo C; Prados J; Marchal JA; Vélez C; Carrillo E; Boulaiz H; Sánchez-Montesinos I; Madeddu R; Aránega A
    Neoplasma; 2003; 50(2):91-6. PubMed ID: 12740641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of a human rhabdomyosarcoma cell line after antineoplastic drug treatment.
    Melguizo C; Prados J; Aneiros J; Fernandez JE; Velez C; Aranega A
    J Pathol; 1995 Jan; 175(1):23-9. PubMed ID: 7891223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance and rhabdomyosarcoma (Review).
    Melguizo C; Prados J; Rama AR; Ortiz R; Álvarez PJ; Fernández JE; Aranega A
    Oncol Rep; 2011 Oct; 26(4):755-61. PubMed ID: 21687952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of myogenic differentiation in a human rhabdomyosarcoma cell line by a new derivative of 5-fluorouracil (QF-3602).
    Marchal JA; Melguizo C; Prados J; Aránega AE; Gómez JA; Campos J; Gallo MA; Espinosa A; Arena N; Aránega A
    Jpn J Cancer Res; 2000 Sep; 91(9):934-40. PubMed ID: 11011122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
    Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
    J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
    Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
    Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
    Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of drug resistance in human rhabdomyosarcoma cell lines is associated with increased maturation: possible explanation for differentiation in recurrences?
    Leuschner I; Heuer T; Harms D
    Pediatr Dev Pathol; 2002; 5(3):276-82. PubMed ID: 12007020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression.
    Chao CC
    FEBS Lett; 1995 Oct; 373(3):285-90. PubMed ID: 7589484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actin, tropomyosin and alpha-actinin as markers of differentiation in human rhabdomyosarcoma cell lines induced with dimethyl sulfoxide.
    Prados J; Melguizo C; Fernandez JE; Aranega AE; Alvarez L; Aranega A
    Cell Mol Biol (Noisy-le-grand); 1993 Jul; 39(5):525-36. PubMed ID: 8374504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells.
    Marchal JA; Prados J; Melguizo C; Gómez JA; Campos J; Gallo MA; Espinosa A; Arena N; Aránega A
    Br J Cancer; 1999 Feb; 79(5-6):807-13. PubMed ID: 10070873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of P-glycoprotein in heat- and/or drug-resistant hepatoma variants.
    Pirity M; Hevér-Szabó A; Venetianer A
    Cytotechnology; 1996; 19(3):207-14. PubMed ID: 8862008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.